manufacturing schedules throughout the year. As a result, we are sustaining full operations in Plant 1 to 3 and successfully ramping up Plant 4, a super plant with 240kL capacity that began its full operation in June 2023. Given the current manufacturing schedule and its rising utilization rate, we anticipate that revenue contribution from Plant 4 will account for approximately 20% of our total DS revenue this year. Furthermore, we are making scheduled progress in the construction of Plant 5 so that it can begin its operations as planned in April 2025, and we are actively engaged in pre-sales activities focused around big pharma clients, similar to our sales approach for Plant 4. As a result of our robust sales execution encompassing all five facilities, we achieved notable milestones including signing contracts with global biopharma companies in the first quarter. Additionally, we have inked a CDO contract with LigaChem Biosciences, formerly LegoChem Biosciences, to collaborate on the development of ADC therapeutics. In March, Samsung Biologics received the 2024 CDMO Leadership Awards presented by Outsourced Pharma and Life Science Connect in recognition of our service and business excellence as a global CDMO company. Based on industry clients' evaluations, we have been awarded in all six performance categories: Quality, Reliability, Capabilities, Expertise, Compatibility, and Service Capabilities. We believe that winning the award for 11 consecutive years demonstrates our dedication to client satisfaction and the strong trust we have built with our clients. For the rest of the year, we will remain committed to accelerating our sales operations by leveraging our outstanding CDMO capabilities and track record, and we look forward to providing you with more positive news regarding contract executions.Portfolio Expansion: Continued investments in laying the groundwork for emerging technologies, ADCAs part of our business portfolio expansion, we have recently increased our investment focus in the ADC area. First of all, we will launch development and manufacturing services for ADC therapeutics, both in clinical and commercial stages, utilizing our standalone, dedicated ADC facility that is expected to be operational within 2024. In addition, we are continuing to invest in promising biotech companies in Korea and throughout the world via the Samsung Life Science Fund, a fund jointly established with Samsung C&T and Samsung Bioepis. Following our investments in companies equipped with ADC technology, such as Araris Biotech in Switzerland and AimedBio in Korea, we also invested in BrickBio, a U.S. based company with ADC and CGT technologies in March. In addition to ADC, we plan to study diverse business opportunities across various areas including AAV. Our aim is to accelerate our platform and business growth by investing in ADC facilities and forming strategic partnerships with biotech companies that have advanced and promising ADC technologies.Biosimilar Business: Preparing for product launches and starting direct salesSamsung Bioepis is also making tremendous strides by consistently expanding the coverage of existing products while simultaneously pursuing various initiatives including the development and release of new pipelines as well as starting directs sales in Korea. In January of this year, Samsung Bioepis received the biologics license application (BLA) approval from the Korean Ministry of Food and Drug Safety (MFDS) for SB12 (Soliris biosimilar), which was launched in several European markets in July of last year, and launched the product on April 1st in Korea, marking a step towards direct sales. Additionally, in February, Samsung Bioepis announced a partnership with Samil Pharmaceutical to co-deliver its SB15 (Eylea biosimilar) to the market after receiving BLA approval from MFDS for SB15 as the first Korean company. With this approval, Samsung Bioepis became the first company in Korea that have obtained BLA app